Home
Home
Welcome to PLANET-2.com
Groundbreaking study on prophylactic platelet transfusions in newborns
Welcome to PLANET-2.com, the official website of the world's only randomized, controlled trial evaluating the threshold level of effectiveness of prophylactic platelet transfusions in newborns. Our study, known as PLANET-2 (Platelets and Neonatal Transfusion Study), is a milestone in the field of neonatology and transfusionology to improve the health and survival of the youngest patients.
About the PLANET-2 study
PLANET-2 is a study conducted in response to pressing questions about the optimal use of platelet transfusions in newborns, especially those born prematurely or with serious medical conditions. Our primary goal is to determine what threshold level of platelets is most effective in preventing bleeding while minimizing the risk of transfusion-related complications.
Our Mission
PLANET-2's mission is to provide the solid, scientific evidence necessary to develop guidelines and standards of care that can save lives and improve the health of newborns around the world. Through our research, we aim to give neonatologists the tools they need to make informed and best-informed decisions about the care of their youngest patients.
Study Methodology
The PLANET-2 study uses a randomized and controlled methodology, meaning that newborns will be randomly assigned to intervention and control groups. This type of approach eliminates bias and produces the most reliable results.
Recruitment of participants: Eligible newborns are recruited from hospitals and neonatology units around the world.
Group allocation: Participants are randomly assigned to one of two groups: those receiving platelet transfusion at higher or lower threshold platelet levels.
Monitoring and data collection: Each child is carefully monitored, and data on their health and clinical course are systematically collected and analyzed.